MECHANISM OF ACTION OF ANTIMYCOBACTERIAL ACTIVITY OF THE NEW BENZOXAZINORIFAMYCIN KRM-1648

The mechanism of antimicrobial activity of KRM-1648 (KRM), a new rifamycin derivative with potent antimycobacterial activity, was studied. Both KRM and rifampin (RMP) inhibited RNA polymerases from Escherichia coli and Mycobacterium avium at low concentrations: the 50% inhibitory concentrations (IC(50)s) of KRM and RMP for E. coli RNA polymerase were 0.13 and 0.10 mu g/ml, respectively, while the IC(50)s for M. avium RNA polymerase were 0.20 and 0.07 mu g/ml. Both KRM and RMP exerted weak inhibitory activity against Mycobacterium fortuitum RNA polymerase, rabbit thymus RNA polymerases, E. coli DNA polymerase I, and two types of reverse transcriptases. Uptake of C-14-KRM by M. avium reached 18,000 dpm/mg (dry weight) 1.5 h after incubation, while uptake by E. coli cells was slight. KRM was much more effective in inhibiting uptake of C-14-uracil than was RMP (IC50 of KRM, 0.04 mu g/ml; IC50 of RMP, 0.12 mu g/ml). These findings suggest, first, that the potent antimycobacterial activity of KRM is due to inhibition of bacterial RNA polymerase and, second, that the activity of KRM against target organisms depends on target cell wall permeability.